Evidence map›Paper›PMID 30073642›Full record

ArticleJournal of neuro-oncology2018

Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.

Rimas V Lukas, Jordi Rodon, Kevin Becker, Eric T Wong, Kent Shih, Mehdi Touat, Marcella Fassò, Stuart Osborne, Luciana Molinero, Carol O'Hear and 2 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01375842 (A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab), which is not on this map. Cited by 104 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01375842 phase1completednot on this map

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

TypeinterventionalSponsorGenentech, Inc.Ran2011 to 2018Enrolled661ConditionsTumors, Hematologic MalignanciesArmsAtezolizumab
3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  14. Trial
  15. Review
  16. Review
  17. Review
  18. Emerging therapies for glioblastoma.Journal of neuro-oncology · 2025
    Review
  19. Review
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rimas V LukasDepartment of Neurology, Northwestern University, 710 N. Lake Shore Drive, Abbott Hall 1114, Chicago, IL, 60611, USA. rimas.lukas@nm.org.
Jordi RodonVall D'Hebron Institute of Oncology, Barcelona, Spain.
Kevin BeckerYale School of Medicine, New Haven, USA.
Eric T WongBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Kent ShihSarah Cannon Research Institute, Nashville, USA.
Mehdi TouatGustave Roussy, Villejuif, France.
Marcella FassòGenentech, Inc., South San Francisco, USA.
Stuart OsborneF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Luciana MolineroGenentech, Inc., South San Francisco, USA.
Carol O'HearGenentech, Inc., South San Francisco, USA.
William GrossmanGenentech, Inc., South San Francisco, USA.
Joachim BaehringYale School of Medicine, New Haven, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlioblastoma is the most common primary malignant brain tumor. No standard treatment exists for recurrent disease. Glioblastoma is associated with an immunosuppressive tumor microenvironment. Immune checkpoint inhibitors, including atezolizumab (anti-programmed death-ligand 1), have demonstrated clinical activity in various cancers. Here, we present the safety and efficacy of atezolizumab in patients with glioblastoma from the phase 1a PCD4989g clinical trial (NCT01375842).

methodsEligible patients had confirmed recurrent glioblastoma and measurable disease per RANO criteria. Atezolizumab (1200 mg) was administered intravenously every 3 weeks until progression or unacceptable toxicity. Patients were monitored for safety; response was evaluated at least every 6 weeks. Baseline biomarkers were evaluated.

resultsAll 16 patients enrolled had received prior chemotherapy, and 50% prior bevacizumab. Ten patients (63%) experienced a treatment-related event. No treatment-related grade 4-5 events were reported. All deaths occurred due to progression or during follow-up. One patient experienced a partial response (5.3 months); 3 experienced disease stabilization. The median overall survival was 4.2 months (range 1.2 to 18.8+ months). Association between peripheral CD4+ T cells and efficacy was observed. Two patients with IDH1-mutant tumors and 1 with a POLE-mutant tumor experienced ≥ 16 months survival.

conclusionsAtezolizumab was safe and well tolerated in this group of patients with recurrent glioblastoma. Our preliminary findings suggest that biomarkers, including peripheral CD4+ T cells and hypermutated tumor status, may help guide selection of patients with recurrent glioblastoma who might receive most benefit from atezolizumab therapy, supporting further atezolizumab combination studies in glioblastoma.

Indexed as

Administration, IntravenousAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBiomarkers, TumorBrain NeoplasmsDNA Polymerase IIFemaleFollow-Up StudiesGlioblastomaHumansIsocitrate DehydrogenaseLipidsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsatezolizumabBevacizumabBiomarkers, TumorDNA Polymerase IIIDH1 protein, humanIsocitrate DehydrogenaseLipidsmutalipocin IPOLE protein, humanPoly-ADP-Ribose Binding ProteinsAtezolizumabGlioblastoma (GBM)Programmed death-ligand 1 (PD-L1)Tumor mutational burden (TMB)

Identifiers

PMID30073642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.